Business Wire News Releases | North Bay Nugget

Stallergenes Greer Publishes in the Lancet Regional Health-Europe Landmark EfficAPSI Real-world Study Confirming Significant Benefit of Its Liquid Sublingual AIT on the Onset and Progression of Allergic Asthma

EfficAPSI is a real-world study with the largest number of patients follow-up to date in the field of allergen immunotherapy (AIT).1 The rigorous methodology used in this study provides important insights about Stallergenes Greer SLIT-liquid as allergic asthma disease-modifying medicine. 1 In this study, treatment with Stallergenes Greer SLIT-liquid was associated with a one-third reduction in the incidence of new asthma events in patients, with or without a history of asthma. 1 The findings confirm the real-life long-term effectiveness of personalised SLIT-liquid for the treatment of allergic rhinitis patients (above the age of 5), with and without pre-existing asthma, regardless the allergen. They substantiate SLIT-liquid as a relevant causal treatment option to prevent both asthmatic disease onset and progression. 1 By demonstrating the benefit on the onset and worsening of asthma, SLIT-liquid treatments confirm their impact in terms of public health. 1 BAAR, Switzerland — Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced that results of its EfficAPSI real-world study evaluating the impact of Stallergenes Greer liquid sublingual AIT (SLIT-liquid) on asthma onset and evolution in patients with allergic rhinitis have been published in the Lancet Regional Health-Europe. The publication is available online ( https://doi.org/10.1016/j.lanepe.2024.100915 ) and will be available in print at a later date.